Disc Medicine price target raised to $153 from $132 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Disc Medicine (IRON) to $153 from $132 and keeps an Overweight rating on the shares. Disc Medicine announced it was one of the initial recipients of FDA Commissioner’s National Priority Voucher for bitopertin in erythropoietic protoporphyria, the analyst tells investors in a research note. A key advantage is that there is a higher likelihood of approval, the firm says.